Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02935907 · ClinicalTrials.gov registry record · Phase 1
APG-115 in Patients With Advanced Solid Tumors or Lymphomas
A Phase 1 study, sponsored by Ascentage Pharma Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT02935907 is a Phase 1 study that has completed, run by Ascentage Pharma Group. The registered enrollment target is 50 participants.
The verdict
NCT02935907, a Phase 1 study, has completed, sponsored by Ascentage Pharma Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
APG-115 is a novel, orally active small-molecule mouse double minute 2 homolog (MDM2) inhibitor. Mechanistically, APG-115 increases p53 and p21 overexpression, activates p53 - mediated apoptosis in tumor cells retaining wild-type p53. APG-115 has shown strong dose- and schedule-dependent antitumor activities in multiple human cancer xenograft and a patient derived xenograft (PDX) models. The preclinical data generated from APG-115 suggest that it may have a broad therapeutic potential for the treatment of human cancer as a single agent and in combination with other classes of anticancer drugs. APG-115 is intended for the treatment of patients with advanced solid tumors and lymphomas. Upon completion of the Phase 1 dose escalation study to establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and/or recommended phase 2 dose (RP2D), several phase Ib/II studies will be implemented accordingly.
Interventions
- DRUG APG-115
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2016-10 |
| Est. Completion | 2019-06-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02935907
The ClinicalTrials.gov registry entry for NCT02935907 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascentage Pharma Group, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which APG-115 is the first listed.
NCT02935907 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02935907 about?
NCT02935907 is a clinical study titled "APG-115 in Patients With Advanced Solid Tumors or Lymphomas". APG-115 is a novel, orally active small-molecule mouse double minute 2 homolog (MDM2) inhibitor. Mechanistically, APG-115 increases p53 and p21 overexpression, activates p53 - mediated apoptosis in tumor cells retaining wild-type p53. APG-115 has shown strong dose- and schedule-dependent antitumor a...
What is the current status of trial NCT02935907?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2016-10. Estimated completion is 2019-06-28.
What interventions are being tested in trial NCT02935907?
The interventions under investigation include: APG-115 (DRUG).
Who is sponsoring clinical trial NCT02935907?
This trial is sponsored by Ascentage Pharma Group, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.